Abstract
Sepsis associated Acute Kidney Injury (SA-AKI) is the leading cause of AKI in the hospital setting and its incidence is increasing. Although the exact pathophysiology and phenotype of SA-AKI are not known, it is widely accepted that SA-AKI has a multi-injury pathway. This form of AKI has components of ischemia-reperfusion injury, direct inflammatory injury, coagulation and endothelial cell dysfunction, and apoptosis. As such, multiple agents have been shown in pre-clinical studies to ameliorate SA-AKI, but there are no interventions currently available for the treatment of SA-AKI. Promising agents that are in development include toll-like receptor inhibition, IL-10 augmentation, modulators of the protein C pathway, and mesenchymal stem cell mediated therapeutics. The aim of this review is to review the pathophysiology of SA-AKI and the therapeutic interventions that are under development to treat this complex and morbid disease.
Keywords: Sepsis associated acute kidney injury, inflammation, IL-6, toll-like receptors, IL-10, ischemia reperfusion injury, apoptosis, activated protein C, soluble thrombomodulin, ethyl pyruvate
Current Drug Targets
Title: Novel Therapeutic Targets for Prevention and Therapy of Sepsis Associated Acute Kidney Injury
Volume: 10 Issue: 12
Author(s): Christian H. Pelte and Lakhmir S. Chawla
Affiliation:
Keywords: Sepsis associated acute kidney injury, inflammation, IL-6, toll-like receptors, IL-10, ischemia reperfusion injury, apoptosis, activated protein C, soluble thrombomodulin, ethyl pyruvate
Abstract: Sepsis associated Acute Kidney Injury (SA-AKI) is the leading cause of AKI in the hospital setting and its incidence is increasing. Although the exact pathophysiology and phenotype of SA-AKI are not known, it is widely accepted that SA-AKI has a multi-injury pathway. This form of AKI has components of ischemia-reperfusion injury, direct inflammatory injury, coagulation and endothelial cell dysfunction, and apoptosis. As such, multiple agents have been shown in pre-clinical studies to ameliorate SA-AKI, but there are no interventions currently available for the treatment of SA-AKI. Promising agents that are in development include toll-like receptor inhibition, IL-10 augmentation, modulators of the protein C pathway, and mesenchymal stem cell mediated therapeutics. The aim of this review is to review the pathophysiology of SA-AKI and the therapeutic interventions that are under development to treat this complex and morbid disease.
Export Options
About this article
Cite this article as:
Pelte H. Christian and Chawla S. Lakhmir, Novel Therapeutic Targets for Prevention and Therapy of Sepsis Associated Acute Kidney Injury, Current Drug Targets 2009; 10 (12) . https://dx.doi.org/10.2174/138945009789753219
DOI https://dx.doi.org/10.2174/138945009789753219 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology Protective Effects of Curcumin against Iron-induced Toxicity
Current Pharmaceutical Biotechnology Employing New Cellular Therapeutic Targets for Alzheimers Disease: A Change for the Better?
Current Neurovascular Research The Application of Angiotensin Converting Enzyme Inhibitors in Heart Surgery
Letters in Drug Design & Discovery The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets The Role of MIF in Hepatic Function, Oxidative Stress, and Inflammation in Thioacetamide-induced Liver Injury in Mice: Protective Effects of Betaine
Current Medicinal Chemistry Development of New Fibrinolytic Agents
Current Pharmaceutical Design Anti-inflammatory Treatment of Acute Coronary Syndromes
Current Pharmaceutical Design Therapeutic Hypothermia in Brain Injuries and Related Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Computational Insights into the Role of Glutathione in Oxidative Stress
Current Neurovascular Research Oxidative Stress and Post-Stroke Depression: Possible Therapeutic Role of Polyphenols?
Current Medicinal Chemistry Patents Review in siRNA Delivery for Pulmonary Disorders
Recent Patents on Drug Delivery & Formulation CD44 and its Role in Inflammation and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Coronary Atherosclerosis and Acute Coronary Syndrome: New Insights from Angioscopic Viewpoints
Vascular Disease Prevention (Discontinued) MMP Inhibitors in Cardiac Diseases: An Update
Recent Patents on Cardiovascular Drug Discovery Delivering RNA Interference to the Mammalian Brain
Current Gene Therapy Comparison of Artemisia annua Bioactivities between Traditional Medicine and Chemical Extracts
Current Bioactive Compounds Neuroprotective Effects of a Glutathione Depletor in Rat Post-Ischemic Reperfusion Brain Damage
CNS & Neurological Disorders - Drug Targets Collateral Circulation in Chronic Total Occlusions – an interventional perspective
Current Cardiology Reviews Protective Effects of Intermedin On Cardiovascular, Pulmonary and Renal Diseases: Comparison with Adrenomedullin and CGRP
Current Protein & Peptide Science